S. Royant-parola, Prise en charge de l'insomnie, 2017.

E. Pierre, L'électricité des songes, p.27, 2018.

J. M. Zeitzer, Control of sleep and wakefulness in health and disease, Prog Mol Biol Transl Sci, pp.137-154, 2013.

M. Xu, S. Chung, S. Zhang, P. Zhong, C. Ma et al., Basal forebrain circuit for sleep-wake control, Nat Neurosci, pp.1641-1647, 2015.

J. E. Sherin, J. K. Elmquist, F. Torrealba, and C. B. Saper, Innervation of histaminergic tuberomammillary neurons by GABAergic and galaninergic neurons in the ventrolateral preoptic nucleus of the rat, J Neurosci Off J Soc Neurosci, pp.4705-4721, 1998.

D. Nitz and J. Siegel, GABA release in the dorsal raphe nucleus: role in the control of REM sleep, Am J Physiol, pp.451-455, 1997.

C. Anaclet, L. Ferrari, E. Arrigoni, C. E. Bass, C. B. Saper et al., GABAergic parafacial zone is a medullary slow-wave-sleep promoting center, Nat Neurosci, pp.1217-1224, 2014.

F. Muindi, J. M. Zeitzer, and H. C. Heller, Retino-hypothalamic regulation of lightinduced murine sleep, Front Syst Neurosci, p.135, 2014.

V. Garcia, S. Libourel, P. , L. M. Grassi, D. Luppi et al., Genetic inactivation of glutamate neurons in the rat sublaterodorsal tegmental nucleus recapitulates REM sleep behaviour disorder, Brain J Neurol, pp.414-428, 2017.

M. G. Lee, O. K. Hassani, and B. E. Jones, Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle, J Neurosci Off J Soc Neurosci, vol.6716, issue.6720, 2005.

A. R. Adamantidis, F. Zhang, A. M. Aravanis, K. Deisseroth, and L. De-lecea, Neural substrates of awakening probed with optogenetic control of hypocretin neurons, 2007.

J. Costentin, Bulletin de l'académie nationale de médecine, 2011.

M. Billiard and Y. , Dauvilliers. Insomnie. Encyclopédie Médico-Chirurgicale, 2004.

J. Doucet and M. Kerkhofs, Exploration du sommeil chez l'adulte et l'adolescent Sleep investigations in adults and adolescents, 2004.

, Prise en charge du patient adulte se plaignant d'insomnie en médecine générale. Recommandations, SFTG -HAS, pp.5-27, 2006.

C. Hausser-hauw, Hypersomnie et insomnie chez l'adulte, 2014.

D. Léger and P. Ogrizek, Troubles du sommeil et de l'éveil : mise au point. La revue de médecine interne, pp.525-531, 2012.

D. Riemann, C. Baglioni, C. Bassetti, B. Bjorvatn, D. Groselj et al., European guideline for the diagnosis and treatment of insomnia, J Sleep Res, pp.675-700, 2017.

A. Y. Avidan and D. N. Neubauer, Chronic Insomnia Disorder: Contin Lifelong Learn Neurol, pp.1064-1092, 2017.

M. E. Thase, Correlates and consequences of chronic insomnia. Gen Hosp Psychiatry. 100!112, 2005.

A. Hoang and D. Gravel, Gestion des hypnosédatifs en UCDG. Regroupement des unités de courte durée gériatriques et des services hospitaliers de gériatrie (RUSHGQ), 2017.

L. Garma and A. J. , Du neuf et du moins neuf sur les insomnies du sujet dépressif, Médecine Sommeil, pp.12-22, 2006.

A. N. Vgontzas, J. Fernandez-mendoza, D. Liao, and E. O. Bixler, Insomnia with objective short sleep duration: The most biologically severe phenotype of the disorder, Sleep Med Rev, pp.241-54, 2013.

M. Kerkhofs, Troubles du sommeil de l'adulte et de l'adolescent, 2015.

Y. Wang, R. Li, X. Wu, F. Zhu, Y. Takata et al., Fasting activated histaminergic neurons and enhanced arousal effect of caffeine in mice, Pharmacol Biochem Behav, pp.164-173, 2015.

J. Grenier and M. Jolin, Le traitement de l'insomnie, 2010.

C. M. Morin and R. Benca, Chronic insomnia. The Lancet. 1129!1141, 2012.

E. N. Ringdahl, S. L. Pereira, and J. E. Delzell, Treatment of primary insomnia, J Am Board Fam Pract, pp.212-219, 2004.

S. Schutte-rodin, L. Broch, D. Buysse, C. Dorsey, and M. Sateia, Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults, J Clin Sleep Med, pp.487-504, 2008.

C. Shah, T. R. Sharma, and A. Kablinger, Controversies in the use of second generation antipsychotics as sleep agent, Pharmacol Res, pp.1-8, 2014.

L. Meurice, C. Junot, G. Lefebvre, V. Bayon, M. Strauss et al., Efficacité de la thérapie comportementale et cognitive (TCCi) dans l'insomnie et dépression comorbide, 2017.

D. N. Neubauer, S. R. Pandi-perumal, D. W. Spence, K. Buttoo, and J. M. Monti, Pharmacotherapy of Insomnia. J Cent Nerv Syst Dis, pp.1-7, 2018.

L. Frase, C. Nissen, D. Riemann, and K. Spiegelhalder, Making sleep easier: pharmacological interventions for insomnia, Expert Opin Pharmacother, pp.1465-1473, 2018.

T. Atkin, S. Comai, and G. Gobbi, Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery, 2018.

S. M. Stahl, Selective Histamine H1 Antagonism: Novel Hypnotic and Pharmacologic Actions Challenge Classical Notions of Antihistamines, CNS Spectr, pp.1027-1038, 2008.

A. D. Krystal, E. Richelson, and T. Roth, Review of the histamine system and the clinical effects of H1 antagonists: Basis for a new model for understanding the effects of insomnia medications, Sleep Med Rev, pp.263-272, 2013.

N. Zisapel, Drugs for insomnia, Expert Opin Emerg Drugs, pp.299-317, 2012.

O. Benoit, Bénéfices et inconvénients des hypnotiques, Neurophysiol Clin Neurophysiol, pp.245-265, 1991.

B. Ebert, K. A. Wafford, and S. Deacon, Treating insomnia: Current and investigational pharmacological approaches, Pharmacol Ther, pp.612-629, 2006.

J. Minkel and A. D. Krystal, Optimizing the Pharmacologic Treatment of Insomnia, Sleep Med Clin, vol.333, p.350, 2013.

M. Soyka, Treatment of Benzodiazepine Dependence, N Engl J Med, 1147.

. Ansm, Plan d'actions de l'ANSM visant à réduire le mésusage des benzodiazépines, 2012.

. Ansm, Séance n°9 Commission des stupéfiants et psychotropes, 2014.

, ANSM. Lettre aux professionnels de santé : Zolpidem (Edluar®, Stilnox® et génériques): nouvelles conditions de prescription et délivrance, 2017.

M. Cao and M. Chow, The hypocretin/orexin system in sleep disorders: preclinical insights and clinical progress, Nat Sci Sleep, p.81, 2016.

J. Parish and J. Lee-iannotti, Suvorexant: a promising, novel treatment for insomnia, Neuropsychiatr Dis Treat, p.491, 2016.

M. Lancel, Role of GABAA receptors in the regulation of sleep: initial sleep responses to peripherally administered modulators and agonists, Sleep, pp.33-42, 1999.

J. Lu and M. A. Greco, Sleep circuitry and the hypnotic mechanism of GABAA drugs, J Clin Sleep Med, pp.19-26, 2006.

T. Roth, D. Mayleben, B. C. Corser, and N. N. Singh, Daytime pharmacodynamic and pharmacokinetic evaluation of low-dose sublingual transmucosal zolpidem hemitartrate, Hum Psychopharmacol, pp.13-20, 2008.

C. B. Saper, T. E. Scammell, and J. Lu, Hypothalamic regulation of sleep and circadian rhythms, Nature, 1257.

A. D. Krystal, A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: The empirical basis for U.S. clinical practice, Sleep Med Rev. 265!, vol.274, 2009.

K. A. Wafford and B. Ebert, Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time, Nat Rev Drug Discov, vol.530, p.540, 2008.

D. F. Smith, S. Dyve, L. Minuzzi, S. Jakobsen, O. L. Munk et al., Inhibition of [11C]-mirtazapine binding by ?2-adrenoceptor antagonists studied by positron emission tomography in living porcine brain, 2006.

R. F. Orzechowski, D. S. Currie, and C. A. Valancius, Comparative anticholinergic activities of 10 histamine H1 receptor antagonists in two functional models, Eur J Pharmacol, pp.257-264, 2005.

L. H. Tecott, L. M. Sun, S. F. Akana, A. M. Strack, D. H. Lowenstein et al., Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors, Nature, pp.542-546, 1995.

B. Wang and F. F. Chehab, Deletion of the serotonin 2c receptor from transgenic mice overexpressing leptin does not affect their lipodystrophy but exacerbates their diet-induced obesity, Biochem Biophys Res Commun, pp.418-423, 2006.

H. Haas and P. Panula, The role of histamine and the tuberomamillary nucleus in the nervous system, Nat Rev Neurosci, pp.121-130, 2003.

H. L. Haas, O. A. Sergeeva, and O. Selbach, Histamine in the Nervous System, Physiol Rev, pp.1183-1241, 2008.

M. I. Strakhova, A. L. Nikkel, A. M. Manelli, G. C. Hsieh, T. A. Esbenshade et al., Localization of histamine H4 receptors in the central nervous system of human and rat, Brain Res, pp.41-48, 2009.

S. Wong, Protein Selectivity Is Regulated by Multiple Intracellular Regions of GPCRs, Neurosignals, pp.1-12, 2003.

S. Kanba and E. Richelson, Histamine H1 receptors in human brain labelled with [3H]-Doxepin, Brain Res, pp.1-7, 1984.

M. L. Bouthenet, M. Ruat, N. Sales, M. Garbarg, and J. C. Schwartz, A detailed mapping of hist amine H1-receptors in guinea-pig central nervous system established by autoradiography with, 1988.

A. Bárbara, J. Aceves, and J. Arias-montaño, Histamine H1 receptors in rat dorsal raphe nucleus: pharmacological characterisation and linking to increased neuronal activity, Brain Res, pp.247-55, 2002.

T. M. Korotkova, O. A. Sergeeva, A. A. Ponomarenko, and H. L. Haas, Histamine excites noradrenergic neurons in locus coeruleus in rats, Neuropharmacology, pp.129-134, 2005.

M. Cecchi, M. B. Passani, L. Bacciottini, P. F. Mannaioni, and P. Blandina, Cortical acetylcholine release elicited by stimulation of histamine H 1 receptors in the nucleus basalis magnocellularis: a dual-probe microdialysis study in the freely moving rat: Facilitation of acetylcholine release by histamine, Eur J Neurosci, pp.68-78, 2001.

J. Lin, K. Sakai, and M. Jouvet, Evidence for histaminergic arousal mechanisms in the hypothalamus of cat, 1988.

J. Arrang, M. Garbarg, and J. Schwartz, Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor, Nature, pp.832-837, 1983.

J. M. Monti, H. Jantos, M. Boussard, H. Allier, C. Orellana et al., Effects of selective activation or blockade of the histamine H3 receptor on sleep and wakefulness, Eur J Pharmacol, pp.283-287, 1991.

M. B. Passani, J. Lin, A. Hancock, S. Crochet, and P. Blandina, The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders, Trends Pharmacol Sci, pp.618-625, 2004.

K. S. Eriksson, O. Sergeeva, R. E. Brown, and H. L. Haas, Orexin/Hypocretin Excites the Histaminergic Neurons of the Tuberomammillary Nucleus, J Neurosci, pp.9273-9279, 2001.

K. Okakura, A. Yamatodani, T. Mochizuki, A. Horii, and H. Wada, Glutamatergic regulation of histamine release from rat hypothalamus, Eur J Pharmacol, pp.189-192, 1992.

K. S. Eriksson, D. R. Stevens, and H. L. Haas, Serotonin excites tuberomammillary neurons by activation of Na+/Ca2+-exchange, Neuropharmacology, pp.345-351, 2001.

J. Lin, Y. Hou, K. Sakai, and M. Jouvet, Histaminergic descending inputs to the mesopontine tegmentum and their role in the control of cortical activation and wakefulness in the cat, J Neurosci, pp.1523-1537, 1996.

Z. Huang, T. Mochizuki, W. Qu, Z. Hong, T. Watanabe et al., Altered sleep-wake characteristics and lack of arousal response to H3 receptor antagonist in histamine H1 receptor knockout mice, Proc Natl Acad Sci, pp.4687-4692, 2006.

J. S. Lin, K. Sakai, and M. Jouvet, Hypothalamo-preoptic Histaminergic Projections in Sleep-Wake Control in the Cat, Eur J Neurosci, pp.618-625, 1994.

V. Ramesh, M. M. Thakkar, R. E. Strecker, R. Basheer, and R. W. Mccarley, Wakefulness-inducing effects of histamine in the basal forebrain of freely moving rats, Behav Brain Res, pp.271-278, 2004.

P. B. Reiner and A. Kamondi, Mechanisms of antihistamine-induced sedation in the human brain: H1 receptor activation reduces a background leakage potassium current, Neuroscience, pp.579-588, 1994.

P. Lagos, J. M. Monti, H. Jantos, and P. Torterolo, Microinjection of the melaninconcentrating hormone into the lateral basal forebrain increases REM sleep and reduces wakefulness in the rat, Life Sci, pp.895-899, 2012.

T. Scammell, D. Gerashchenko, T. Mochizuki, M. Mccarthy, I. Estabrooke et al., An adenosine A2a agonist increases sleep and induces Fos in ventrolateral preoptic neurons, 2001.

R. E. Strecker, S. Morairty, M. M. Thakkar, T. Porkka-heiskanen, R. Basheer et al., Adenosinergic modulation of basal forebrain and preoptic/anterior hypothalamic neuronal activity in the control of behavioral state, Behav Brain Res, pp.183-204, 2000.

M. M. Thakkar, S. C. Engemann, K. M. Walsh, and P. K. Sahota, Adenosine and the homeostatic control of sleep: Effects of A1 receptor blockade in the perifornical lateral hypothalamus on sleep-wakefulness, 2008.

L. Tuomisto and J. Tuomisto, Diurnal variations in brain and pituitary histamine and histamine-N-methyltransferase in the rat and guinea pig, Med Biol, pp.204-209, 1982.

R. Parmentier, H. Ohtsu, Z. Djebbara-hannas, J. Valatx, T. Watanabe et al., Anatomical, Physiological, and Pharmacological Characteristics of Histidine Decarboxylase Knock-Out Mice: Evidence for the Role of Brain Histamine in Behavioral and Sleep-Wake Control, J Neurosci, pp.7695-7711, 2002.

M. Smriga, M. Mori, and K. Torii, Circadian Release of Hypothalamic Norepinephrine in Rats In Vivo Is Depressed during Early L-Lysine Deficiency, J Nutr, pp.1641-1643, 2000.

X. Sun, J. Deng, T. Liu, and J. Borjigin, Circadian 5-HT production regulated by adrenergic signaling, Proc Natl Acad Sci, pp.4686-4691, 2002.

A. D. Smith, R. J. Olson, and J. B. Justice, Quantitative microdialysis of dopamine in the striatum: effect of circadian variation, J Neurosci Methods, pp.33-41, 1992.

L. I. Kiyashchenko, B. Y. Mileykovskiy, N. Maidment, H. A. Lam, M. Wu et al., Release of Hypocretin (Orexin) during Waking and Sleep States, J Neurosci, pp.5282-5286, 2002.

R. M. Salomon, B. Ripley, J. S. Kennedy, B. Johnson, D. Schmidt et al., Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects, Biol Psychiatry, pp.96-104, 2003.

J. M. Zeitzer, C. L. Buckmaster, K. J. Parker, C. M. Hauck, D. M. Lyons et al., Circadian and Homeostatic Regulation of Hypocretin in a Primate Model: Implications for the Consolidation of Wakefulness, J Neurosci, pp.3555-3560, 2003.

R. Mcquade, D. Creton, and S. C. Stanford, Effect of novel environmental stimuli on rat behaviour and central noradrenaline function measured by in vivo microdialysis, Psychopharmacology (Berl), pp.393-400, 1999.

L. E. Rueter, C. A. Fornal, and B. L. Jacobs, A Critical Review of 5-HT Brain Microdialysis and Behavior, Rev Neurosci, pp.117-137, 1997.

P. Bonnavion and L. De-lecea, Hypocretins in the Control of Sleep and Wakefulness, Curr Neurol Neurosci Rep, pp.174-179, 2010.

J. R. Glass, B. A. Sproule, N. Herrmann, and U. E. Busto, Effects of 2-Week Treatment With Temazepam and Diphenhydramine in Elderly Insomniacs: A Randomized, Placebo-Controlled Trial, J Clin Psychopharmacol, pp.182-188, 2008.

C. M. Morin, U. Koetter, C. Bastien, J. C. Ware, and V. Wooten, Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial, 2005.

G. S. Richardson, T. A. Roehrs, L. Rosenthal, G. Koshorek, and T. Roth, Tolerance to daytime sedative effects of H1 antihistamines, J Clin Psychopharmacol, pp.511-515, 2002.

G. Hajak, A. Rodenbeck, U. Voderholzer, D. Riemann, S. Cohrs et al., Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study, J Clin Psychiatry, pp.453-463, 2001.

D. Riemann, U. Voderholzer, S. Cohrs, A. Rodenbeck, G. Hajak et al., Trimipramine in Primary Insomnia: Results of a Polysomnographic Double-Blind Controlled Study, 2002.

T. Roth, R. Rogowski, S. Hull, H. Schwartz, G. Koshorek et al., Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia, 2007.

M. Scharf, R. Rogowski, S. Hull, M. Cohn, D. Mayleben et al., Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in elderly patients with primary insomnia: a randomized, double-blind, placebo-controlled crossover study, J Clin Psychiatry, pp.1557-1564, 2008.

A. D. Krystal, H. H. Durrence, M. Scharf, P. Jochelson, R. Rogowski et al., Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia, pp.1553-1561, 2010.

A. D. Krystal, A. Lankford, H. H. Durrence, E. Ludington, P. Jochelson et al., Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia, pp.1433-1442, 2011.

J. K. Walsh, C. Soubrane, and T. Roth, Efficacy and Safety of Zolpidem Extended Release in Elderly Primary Insomnia Patients, Am J Geriatr Psychiatry, pp.44-57, 2008.

V. Mccall, W. Erman, M. Krystal, A. D. Rosenberg, R. Scharf et al., A polysomnography study of eszopiclone in elderly patients with insomnia, Curr Med Res Opin, pp.1633-1642, 2006.

P. G. Ozdemir, A. S. Karadag, Y. Selvi, M. Boysan, S. G. Bilgili et al., Assessment of the effects of antihistamine drugs on mood, sleep quality, sleepiness, and dream anxiety, Int J Psychiatry Clin Pract, pp.161-168, 2014.

A. M. Mahdy and N. R. Webster, Histamine and antihistamines, Anaesth Intensive Care Med, pp.324-329, 2011.

F. Monczor, N. Fernandez, C. P. Fitzsimons, C. Shayo, and C. Davio, Antihistaminergics and inverse agonism: Potential therapeutic applications, Eur J Pharmacol, pp.26-32, 2013.

F. Simon and K. J. Simons, H1 Antihistamines: Current Status and Future Directions, World Allergy Organ J, pp.145-55, 2008.

F. Simons, Advances in H1-Antihistamines, N Engl J Med, 2004.

S. M. Albert, T. Roth, M. Toscani, M. V. Vitiello, and P. Zee, Sleep Health and Appropriate Use of OTC Sleep Aids in Older Adults : Recommendations of a Gerontological Society of America Workgroup. The Gerontologist, pp.163-170, 2015.

G. Pozzi and C. , Médicaments et risque de glaucome par fermeture de l'angle, J Fr Ophtalmol, pp.91-101, 2002.

J. P. Vande-griend and A. S. , Histamine-1 receptor antagonism for treatment of insomnia, J Am Pharm Assoc, pp.210-219, 2012.

R. Garnier, I. Blanc-brisset, J. Langrand, and A. Villa, Toxicité aiguë de la doxylamine. Revue bibliographique, Toxicol Anal Clin, pp.261-270, 2016.

H. Friedman and D. J. Greenblatt, The pharmacokinetics of doxylamine: use of automated gas chromatography with nitrogen-phosphorus detection, J Clin Pharmacol, pp.448-451, 1985.

H. J. Kim, S. H. Oh, C. S. Youn, J. H. Wee, J. H. Kim et al., The associative factors of delayed-onset rhabdomyolysis in patients with doxylamine overdose, Am J Emerg Med, pp.903-907, 2011.

H. Friedman, D. J. Greenblatt, J. M. Scavone, E. S. Burstein, H. R. Ochs et al., Clearance of the Antihistamine Doxylamine: Reduced in Elderly Men But Not in Elderly Women, Clin Pharmacokinet, pp.312-316, 1989.

G. M. Smith and P. H. Smith, Effects of doxylamine and acetaminophen on postoperative sleep, Clin Pharmacol Ther, pp.549-557, 1985.

F. Sjöqvist and L. Lasagna, The hypnotic efficacy of doxylamine, Clin Pharmacol Ther, pp.48-54, 1967.

A. Roussin, A. Bouyssi, L. Pouché, L. Pourcel, and M. Lapeyre-mestre, Misuse and Dependence on Non-Prescription Codeine Analgesics or Sedative H1 Antihistamines by Adults: A Cross-Sectional Investigation in France, PLoS ONE, p.76499, 2013.

G. Ploussard, E. Paillaud, and P. Mongiat-artus, Alpha-bloquants et anticholinergiques chez le sujet âgé : comment prescrire ? Prog En Urol -FMC, 9!13, 2015.

S. Mebarki and C. Trivalle, Échelles d'évaluation de l'effet anticholinergique des médicaments, NPG Neurol -Psychiatr, 2012.

M. F. Carrascosa, J. Caviedes, M. I. Lucena, and A. Cuadrado-lavin, Syndrome of inappropriate antidiuresis in doxylamine overdose. Case Rep, p.7428, 2012.

M. Júnior, F. Scotti, L. Ishiki, H. Botelho, S. et al., Benzo-and thienobenzo-diazepines: multi-target drugs for CNS disorders, Mini Rev Med Chem, pp.630-647, 2015.

C. Fox, K. Richardson, I. D. Maidment, G. M. Savva, F. E. Matthews et al., Anticholinergic Medication Use and Cognitive Impairment in the Older Population: The Medical Research Council Cognitive Function and Ageing Study: ANTICHOLINERGIC ACTIVITY AND COGNITION, J Am Geriatr Soc, pp.1477-1483, 2011.

B. Bockholdt, E. Klug, and V. Schneider, Suicide through doxylamine poisoning, Forensic Sci Int, 2001.

F. L. Cantrell, A. K. Clark, M. Mckinley, and M. Qozi, Retrospective review of unintentional pediatric ingestions of doxylamine, Clin Toxicol, pp.178-180, 2015.

, ANSM. DONORMYL 15 mg, comprimé pelliculé sécable -Résumé des caractéristiques du produit

. R#rcpsurdosage, , p.6, 2018.

. !-('e!,

C. Köppel, K. Ibe, and U. Oberdisse, Rhabdomyolysis in doxylamine overdose, Lancet Lond Engl, pp.442-443, 1987.

F. S. Mendoza, J. O. Atiba, A. M. Krensky, and L. M. Scannell, Rhabdomyolysis Complicating Doxylamine Overdose, Clin Pediatr (Phila, pp.595-597, 1987.

H. Nonaka, S. Otaki, E. Ohshima, M. Kono, H. Kase et al., Unique binding pocket for KW-4679 in the histamine H1 receptor, Eur J Pharmacol, pp.111-117, 1998.

G. Asnis, M. Thomas, and M. Henderson, Pharmacotherapy Treatment Options for Insomnia: A Primer for Clinicians, Int J Mol Sci, p.50, 2015.

M. Farré, C. Pérez-mañá, E. Papaseit, E. Menoyo, M. Pérez et al., Bilastine vs. hydroxyzine: occupation of brain histamine H1-receptors evaluated by positron emission tomography in healthy volunteers, Br J Clin Pharmacol, pp.970-980, 2014.

D. , intérêt de la Santé publique ma profession avec conscience et de respecter non seulement la législation en vigueur mais aussi les règles de l'Honneur

, De ne jamais oublier ma responsabilité et mes devoirs envers le malade et sa dignité humaine

, De ne dévoiler à personne les secrets qui m'auraient été confiés ou dont j'aurais eu connaissance dans l'exercice de ma Profession

, En aucun cas, je ne consentirai à utiliser mes connaissances et mon état pour corrompre les moeurs et favoriser les actes criminels

, Que les hommes m'accordent leur estime si je suis fidèle à mes promesses. Que je sois méprisé de mes Confrères si je manque à mes engagements

, &,01)2+,-34/&+34)5)/4+,)3)6

!. and -. &. 21=!->.!-?'!, ! (.@(,-5.! 5?-:9, vol.5, p.5

!. &. ,

?. D*!-?'!-:<,

. D*!'9, , p.9

!. ,

!. 5#'(-;-< and ?. @9a-.!-;-!->-!-opip$!-b, , vol.9

!. >d5./>'/<.*!-'<< and -. !. ,

!. &. , D<-?.:!.HH9<'<.:!)'9:!.N5

!. 8#9, , p.9

, ;')9/9A-.:!)'?@(D!?.:!H'9C?.:!>,:.:!-;9?9:D.:$!7.!H'9

!. Hh, !>9)9/-.!?.!(9:A-.!>8'55, vol.9

!. &. , D<-?.:*!

, ! >9), vol.9

, 9<#

!. and /. ,

. !-d;,

D. and -. Gd, , vol.5

!. Nk?,

. !f;, , vol.9

]. !\!-_(!`paotb, @9.!